Application of interleukin-12 expressing dendritic cells for the treatment of animal model of leukemia

Experimental Biology and Medicine

Volumn 234, Issue 8, 2009, Pages 952-960

  Tsai, Bor Yu ^a   Lin, Yu Li ^a   Chiang, Bor Luen ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adenoviral vector; Dendritic cells; Interleukin 12; Leukemia; RL 1

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE EXPRESSION; GENETIC TRANSFECTION; LEUKEMIA; MOUSE; NONHUMAN; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; IMMUNITY, CELLULAR; INTERLEUKIN-12; LEUKEMIA; MICE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINATION;

ANIMALIA; MURINAE; MUS;

EID: 68149092683     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0805-RM-165     Document Type: Article

References (37)

1. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19:203-208, 2007.
2. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201:1503-1517, 2005.
3. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90:3245-3287, 1997.
4. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61:6445-6450, 2001.
5. Akiyama Y, Maruyama K, Nara N, Hojo T, Cheng JY, Mori T, Wiltrout RH, Yamaguchi K. Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters. Cancer Lett 184:37-47, 2002.
6. Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM, Ioannides CG. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 6:4192-4200, 2000.
7. Wang Y, Xie W, Qiu Y, Gu Z, Zhang X. [Antigen loading on dendritic cells affects the cell function in stimulating T cells]. Zhonghua Xue Ye Xue Za Zhi 21:345-348, 2000.
8. Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS, Donninger C, Mason M. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C(12)U] (Ampligen R). Vaccine 21:787-790, 2003.
9. Liu BY, Chen XH, Gu QL, Li JF, Yin HR, Zhu ZG, Lin YZ. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 10:630-633, 2004.
10. Ramirez-Pineda JR, Frohlich A, Berberich C, Moll H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 172:6281-6289, 2004.
11. Maggio R, Peragine N, Calabrese E, De Propris MS, Intoppa S, Della Starza I, Ariola C, Vitale A, Foa R, Guarini A. Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission. Leuk Lymphoma 48:302-310, 2007.
12. Tomihara K, Kato K, Masuta Y, Nakamura K, Uchida H, Sasaki K, Tanaka T, Huang J, Hiratsuka H, Hamada H. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther 15:203-213, 2008.
13. Xue G, Liu RY, Li Y, Cheng Y, Liang ZH, Wu JX, Zeng MS, Tian FZ, Huang W. Dendritic cells modified with 6Ckine/IFNgamma fusion gene induce specific cytotoxic T lymphocytes in vitro. Cancer Immunol Immunother 56:1831-1843, 2007.
14. Yoshikawa T, Niwa T, Mizuguchi H, Okada N, Nakagawa S. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency. Gene Ther 15:1321-1329, 2008.
15. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677-4685, 2007.
16. Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Miyagi T, Jinushi M, Sakamori R, Kohga K, Uemura A, Ohkawa K, Storkus WJ, Hayashi N. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther 14:863-871, 2007.
17. Lee YL, Tao MH, Chow YH, Chiang BL. Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy. Hum Gene Ther 9:457-465, 1998.
18. Lee YL, Ye YL, Yu CI, Wu YL, Lai YL, Ku PH, Hong RL, Chiang BL. Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum Gene Ther 12:2065-2079, 2001.
19. Heller LC, Ingram SF, Lucas ML, Gilbert RA, Heller R. Effect of electrically mediated intratumor and intramuscular delivery of a plasmid encoding IFN alpha on visible B16 mouse melanomas. Technol Cancer Res Treat 1:205-209, 2002.
20. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-154, 1989.
21. Gregory MS, Saff RR, Marshak-Rothstein A, Ksander BR. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand. Cancer Res 67:11951-11958, 2007.
22. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922-3929, 2007.
23. Cheung KJ, Tam W, Chuang E, Osborne MP. Concurrent invasive ductal carcinoma and chronic lymphocytic leukemia manifesting as a collision tumor in breast. Breast J 13:413-417, 2007.
24. Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K. Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia. Eur J Haematol 78:545, 2007.
25. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martinez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM. Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood 111:3377-3382, 2008.
26. Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 15:865-874, 2006.
27. Shiratori I, Suzuki Y, Oshiumi H, Begum NA, Ebihara T, Matsumoto M, Hazeki K, Kodama K, Kashiwazaki Y, Seya T. Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model. Cancer Sci 98:1936-1942, 2007.
28. Siddiqui F, Ehrhart EJ, Charles B, Chubb L, Li CY, Zhang X, Larue SM, Avery PR, Dewhirst MW, Ullrich RL. Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int J Hyperthermia 22:587-606, 2006.
29. Lee JJ, Choi BH, Kang HK, Kim SK, Nam JH, Yang DH, Kim YK, Kim HJ, Chung IJ. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients. Leuk Res 32:1653-1660, 2008.
30. Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos K, Dmoszynska A, Rolinski J. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22:1007-1017, 2008.
31. Kokhaei P, Adamson L, Palma M, Osterborg A, Pisa P, Choudhury A, Mellstedt H. Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors. Cytotherapy 8:318-326, 2006.
32. Nakahara T, Urabe K, Fukagawa S, Uchi H, Inaba K, Furue M, Moroi Y. Engagement of human monocyte-derived dendritic cells into interleukin (IL)-12 producers by IL-1beta + interferon (IFN)-gamma. Clin Exp Immunol 139:476-482, 2005.
33. Schuler G, Steinman RM. Dendritic cells as adjuvants for immunemediated resistance to tumors. J Exp Med 186:1183-1187, 1997.
34. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 62:5260-5266, 2002.
35. Korst RJ, Ailawadi M, Lee JM, Lee S, Yamada R, Mahtabifard A, Crystal RG. Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic transgene. Hum Gene Ther 12:1639-1649, 2001.
36. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245-273, 2000.
37. Lee JC, Kim DC, Gee MS, Saunders HM, Sehgal CM, Feldman MD, Ross SR, Lee WM. Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res 62:747-755, 2002.